IRICoR
Overview
IRICoR is a non-profit drug discovery and commercialization centre that accelerates the transformation of academic research into new therapies for oncology, immunology, and rare diseases.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| RejuvenRx Inc. | Jan 2023 | Seed | Lead |
| ExCellThera | Aug 2020 | Grant | Co-investor |
| Epitopea | Oct 2024 | VC Round | Co-investor |
Key People
Elizabeth Douville
President CEO
Mario Callejo
Vice President, Scientific Operations At IRICoR, Chief Operating Officer (COO)
Jean-Louis Brochu
Director, Intellectual Property And Communications
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is IRICoR based?
IRICoR is headquartered in Montreal, Canada.
When was IRICoR founded?
IRICoR was founded in 2008.
How many portfolio companies does IRICoR have?
IRICoR has 3 portfolio companies in Caplight's dataset.
What are some companies in IRICoR's portfolio?
Portfolio companies visible on Caplight include RejuvenRx Inc., ExCellThera, Epitopea.
What was IRICoR's most recent investment shown here?
IRICoR's most recent investment in this portfolio sample was in Epitopea in 2024.
What sectors does IRICoR focus on?
IRICoR focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does IRICoR focus on?
Stage focus information for IRICoR is not publicly available.